BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33859517)

  • 1. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.
    Deng L; He K; Pan Y; Wang H; Luo Y; Xia Q
    Int J Med Sci; 2021; 18(10):2109-2116. PubMed ID: 33859517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophages as Targets in Hepatocellular Carcinoma Therapy.
    Liu YT; Mao ZW; Ding Y; Wang WL
    Mol Cancer Ther; 2024 Jun; 23(6):780-790. PubMed ID: 38310642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
    Song JS; Chang CC; Wu CH; Dinh TK; Jan JJ; Huang KW; Chou MC; Shiue TY; Yeh KC; Ke YY; Yeh TK; Ta YN; Lee CJ; Huang JK; Sung YC; Shia KS; Chen Y
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
    Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
    Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
    Xia Y; Brown ZJ; Huang H; Tsung A
    Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
    Wei Z; Zhang X; Yong T; Bie N; Zhan G; Li X; Liang Q; Li J; Yu J; Huang G; Yan Y; Zhang Z; Zhang B; Gan L; Huang B; Yang X
    Nat Commun; 2021 Jan; 12(1):440. PubMed ID: 33469052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
    Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of triggering receptor expressed on myeloid cells 1 inhibits invasion and migration of liver cancer cells by mediating macrophage polarization.
    Chen M; Lai R; Lin X; Chen W; Wu H; Zheng Q
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research progress on tumour‑associated macrophages in gastric cancer (Review).
    Zhou Z; Yang Z; Wang J; Wang Q; Zhang H; Ju X
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma.
    Ruan Q; Wang H; Burke LJ; Bridle KR; Li X; Zhao CX; Crawford DHG; Roberts MS; Liang X
    Int J Cancer; 2020 Sep; 147(6):1519-1527. PubMed ID: 32010970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.
    Eisinger S; Sarhan D; Boura VF; Ibarlucea-Benitez I; Tyystjärvi S; Oliynyk G; Arsenian-Henriksson M; Lane D; Wikström SL; Kiessling R; Virgilio T; Gonzalez SF; Kaczynska D; Kanatani S; Daskalaki E; Wheelock CE; Sedimbi S; Chambers BJ; Ravetch JV; Karlsson MCI
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32005-32016. PubMed ID: 33229588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.
    Rizzo A; Ricci AD; Brandi G
    Future Oncol; 2021 Mar; 17(7):755-757. PubMed ID: 33508960
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Liposome-Encapsulated Zoledronic Acid on Microenvironment of Hepatocellular Carcinoma May Depend on the Ratio Between M1 and M2 Polarized Macrophages.
    Wu S; Lin X; Cui X
    Bull Exp Biol Med; 2020 Nov; 170(1):69-74. PubMed ID: 33237530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
    Yang Y; Sun M; Yao W; Wang F; Li X; Wang W; Li J; Gao Z; Qiu L; You R; Yang C; Ba Q; Wang H
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.